A population pharmacodynamic model for lactate dehydrogenase and neuron specific enolase to predict tumor progression in small cell lung cancer patients

AAPS Journal

Volumn 16, Issue 3, 2014, Pages 609-619

  Buil Bruna, Núria ^a   López Picazo, José María ^b   Moreno Jiménez, Marta ^b   Martín Algarra, Salvador ^b   Ribba, Benjamin ^c   Trocóniz, Iñaki F ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c UNIVERSITÉ DE LYON   (France)

Author keywords

biomarkers; lung cancer; mixed effect model; pharmacodynamics; population model

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; LACTATE DEHYDROGENASE; NEURON SPECIFIC ENOLASE; ANTINEOPLASTIC AGENT; ENOLASE; TUMOR MARKER;

ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CLINICAL PRACTICE; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PATIENT MONITORING; PHARMACODYNAMICS; PREDICTION; PREDICTIVE VALUE; BIOLOGICAL MODEL; CARCINOMA, SMALL CELL; DISEASE COURSE; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; POPULATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SMALL CELL; CISPLATIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ETOPOSIDE; HUMANS; L-LACTATE DEHYDROGENASE; LUNG NEOPLASMS; MODELS, BIOLOGICAL; PHOSPHOPYRUVATE HYDRATASE; POPULATION; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84899988808     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-014-9600-0     Document Type: Article

References (47)

1. Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47.
2. Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol. 2004;22(22):4442-5. (Pubitemid 41185107)
3. Villaruz LC, Socinski MA. The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement. Clin Cancer Res. 2013;19(10):2629-36.
4. Bender B, Schindler E, Friberg L. Population pharmacokinetic pharmacodynamic modelling in oncology: a tool for predicting clinical response. Br J Clin Pharmacol. 2013;18(2):e86.
5. Danhof M, Alvan G, Dahl SG, Kuhlmann J, Paintaud G. Mechanism-based pharmacokinetic-pharmacodynamic modeling - a new classification of biomarkers. Pharm Res. 2005;22(9):1432-7. (Pubitemid 41215882)
6. Romero E, de Mendizabal NV, Cendrós J, Peraire C, Bascompta E, Obach R, et al. Pharmacokinetic/pharmacodynamic model of the testosterone effects of triptorelin administered in sustained release formulations in patients with prostate cancer. J Pharmacol Exp Ther. 2012;342(3):788-98.
7. Kogan Y, Halevi-Tobias K, Elishmereni M, Vuk-Pavlović S, Agur Z. Reconsidering the paradigm of cancer immunotherapy by computationally aided real-time personalization. Cancer Res. 2012;72(9):2218-27.
8. Stovold R, Blackhall F, Meredith S, Hou J, Dive C, White A. Biomarkers for small cell lung cancer: neuroendocrine, epithelial and circulating tumour cells. Lung Cancer. 2012;76(3):263-8.
9. Yip D, Harper PG. Predictive and prognostic factors in small cell lung cancer: current status. Lung Cancer. 2000;28(3):173-85. (Pubitemid 30254226)
10. Wójcik E, Kulpa J, Sas-Korczyńska B, Korzeniowski S, Jakubowicz J. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer. Anticancer Res. 2008;28(5B):3027-33.
11. Holdenrieder S, von Pawel J, Dankelmann E, Duell T, Faderl B, Markus A, et al. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. Clin Cancer Res. 2008;14(23):7813-21.
12. Lippert MC, Javadpour N. Lactic dehydrogenase in the monitoring and prognosis of testicular cancer. Cancer. 1981; 48(10):2274-8. (Pubitemid 12231602)
13. Scartozzi M, Faloppi L, Bianconi M, Giampieri R, Maccaroni E, Bittoni A, et al. The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management. PLoS One. 2012;7(3):e32653.
14. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep. 1973;4(2):31-42.
15. Lindstrom MJ, Bates DM. Nonlinear mixed effects models for repeated measures data. Biometrics. 1990;46:673-87. (Pubitemid 20333602)
16. Bauer R. NONMEM users guide introduction to NONMEM 7.2.0. ICON Development Solutions Ellicott City, MD 2011.
17. Lavielle M. MONOLIX (MOdèles NOn LInéaires à effets miXtes). Orsay, France: MONOLIX group; 2005.
18. Jusko WJ, Ko HC, Ebling WF. Convergence of direct and indirect pharmacodynamic response models. J Pharmacokinet Pharmacodyn. 1995;23(1):5-8.
19. Jacqmin P, Snoeck E, Van Schaick E, Gieschke R, Pillai P, Steimer J, et al. Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model. J Pharmacokinet Pharmacodyn. 2007;34(1):57-85. (Pubitemid 46122548)
20. Lindbom L, Pihlgren P, Jonsson N. PsN-Toolkit - a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79(3):241-57. (Pubitemid 41196689)
21. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143-51.
22. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39(4):561-77. (Pubitemid 23118304)
23. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 1999;17(1):409-422. (Pubitemid 29022420)
24. Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11(3):558-69.
25. Lesko LJ, Atkinson Jr A. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies 1. Annu Rev Pharmacol Toxicol. 2001;41(1):347-66. (Pubitemid 32390116)
26. Almufti R, Wilbaux M, Oza A, Henin E, Freyer G, Tod M, et al. A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment. Ann Oncol. 2014;25(1):41-56.
27. Fizazi K, Cojean I, Pignon J, Rixe O, Gatineau M, Hadef S, et al. Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy. Cancer. 1998;82(6):1049-55. (Pubitemid 28136516)
28. Jørgensen L, Osterlind K, Hansen H, Cooper E. The prognostic influence of serum neuron specific enolase in small cell lung cancer. Br J Cancer. 1988;58(6):805.
29. Jørgensen L, Osterlind K, Genolla J, Gomm S, Hernandez J, Johnson P, et al. Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres. Br J Cancer. 1996;74(3):463.
30. Lassen U, Østerlind K, Hirsch F, Bergman B, Dombernowsky P, Hansen H. Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression. Br J Cancer. 1999;79(3/4):515.
31. Østerlind K, Andersen PK. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res. 1986; 46(8):4189.
32. Osterlind K. LDH or NSE or LDH and NSE as pretreatment prognostic factors in small cell lung cancer? A commentary. Lung Cancer. 2000;30(1):51-3.
33. Pinson P, Joos G, Watripont P, Brusselle G, Pauwels R. Serum neuron-specific enolase as a tumor marker in the diagnosis and follow-up of small-cell lung cancer. Respiration. 2009;64(1):102-7.
34. Quoix E, Purohit A, Faller-Beau M, Moreau L, Oster J, Pauli G. Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer. 2000;30(2):127-34.
35. You B, Tranchand B, Girard P, Falandry C, Ribba B, Chabaud S, et al. Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. Lung Cancer. 2008;62(2):261-72.
36. Molina R, Filella X, Auge JM. ProGRP: a new biomarker for small cell lung cancer. Clin Biochem. 2004;37(7):505-11. (Pubitemid 38845013)
37. Warburg O. On the origin of cancer cells. Science. 1956; 123(3191):309-14.
38. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002;2(9):683-93. (Pubitemid 37328919)
39. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029-33.
40. Zhuang L, Scolyer RA, Murali R, McCarthy SW, Zhang XD, Thompson JF, et al. Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins. Mod Pathol. 2010;23(1):45-53.
41. Scatena R, Bottoni P, Pontoglio A, Mastrototaro L, Giardina B. Glycolytic enzyme inhibitors in cancer treatment. 2008.
42. Zhou W, Capello M, Fredolini C, Racanicchi L, Piemonti L, Liotta LA, et al. Proteomic analysis reveals Warburg effect and anomalous metabolism of glutamine in pancreatic cancer cells. J Proteome Res. 2011;11(2):554-63.
43. Giaccone G. Clinical perspectives on platinum resistance. Drugs. 2000;59(4):9-17. (Pubitemid 30344987)
44. Anderlini P, Przepiorka D, Champlin R, Korbling M. Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals. Blood. 1996;88(8):2819-25. (Pubitemid 26357361)
45. Zohlnhöfer D, Ott I, Mehilli J, Schömig K, Michalk F, Ibrahim T, et al. Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction. JAMA:J Am Med Assoc. 2006;295(9):1003-10.
46. Lindemann A, Herrmann F, Oster W, Haffner G, Meyenburg W, Souza LM, et al. Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy. Blood. 1989;74(8):2644-51. (Pubitemid 20007787)
47. Anderlini P, Przepiorka D, Seong D, Miller P, Sundberg J, Lichtiger B, et al. Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. Transfusion. 1996;36(7):590-5. (Pubitemid 26256425)